Headlines

Vertex Pharmaceuticals (VRTX) Q4 2025 (USD): Adj. EPS 5.03 (exp. 5.11), Revenue 3.19bln (exp. 3.18bln); FY26 revenue view 12.95-13.1bln (exp. 13.02bln)

Newsquawk Staff ·

Vertex Pharmaceuticals (VRTX) Q4 2025 (USD): Adj. EPS 5.03 (exp. 5.11), Revenue 3.19bln (exp. 3.18bln); FY26 revenue view 12.95-13.1bln (exp. 13.02bln)

What it means

Vertex Pharmaceuticals missed its adjusted EPS expectations, slightly underperforming the consensus, which could signal pressure on sentiment toward the stock. However, the revenue beat suggests some stability in operations, while guidance for FY26 aligns closely with expectations, indicating management’s confidence amidst mixed results. Investors should monitor how this affects broader biotech sentiment and trading activity in VRTX going forward.

Related headlines